MCED is an emerging set of technologies that, when added to existing single cancer screening, provides an opportunity to identify a broad range of cancers earlier in the course of disease. With the use of a simple blood draw, urine, saliva, or stool sample test, MCED technology enables clinicians to rapidly screen for multiple types of cancer at once, potentially catching and treating them earlier. "Multi-cancer early detection represents a paradigm shift in how cancers will be diagnosed and treated in the future," said Brian Druker, MD, director of the Knight Cancer Institute at Oregon Health & Science University, and a founding member of the MCED forum. "By bringing together this group of experts from across the cancer research, clinical, and patient advocacy landscapes, we intend to evaluate evidence and establish standards for the emerging field of MCED that can guide physicians in adopting the technology in clinical practice. Ultimately, we are united in our mission to evaluate how MCED may benefit patients by identifying their cancer at earlier stages, when they can be more effectively treated."